99149-95-8

Basic information

• Product Name: Saruplase
• Synonyms: Saruplase
• CAS NO: 99149-95-8
• Molecular Weight: 0
• Mol File: 99149-95-8.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Saruplase(CAS DataBase Reference)
• NIST Chemistry Reference: Saruplase(99149-95-8)
• EPA Substance Registry System: Saruplase(99149-95-8)

Safety Data

• Hazardous Substances Data: 99149-95-8(Hazardous Substances Data)

Usage

General Description

Saruplase is a thrombolytic medication that belongs to the class of medications known as tissue plasminogen activators (tPA). It is used in the treatment of heart attacks and certain types of strokes to help dissolve blood clots and restore blood flow to the affected area. Saruplase works by binding to fibrin in blood clots and activating the body's natural clot-dissolving system. This medication is administered intravenously and should be given as soon as possible after the onset of symptoms for the best chance of effectiveness. Common side effects of Saruplase may include bleeding, allergic reactions, and low blood pressure. It is important to use Saruplase under the guidance of a healthcare professional.

Related news

Plasma markers of thrombin activity during coronary thrombolytic therapy with Saruplase (cas 99149-95-8) or urokinase: no prediction of reinfarction07/21/2019

One of the principal problems associated with thrombolytic therapy is rethrombosis of vessels which were initially patent. Although platelets as well as coagulation activation have been implicated in rethrombosis, the specific mechanisms leading to this complication are still unclear. Available ...detailed

Taprostene, a stable prostacyclin analogue, enhances the thrombolytic efficacy of Saruplase (cas 99149-95-8) (recombinant single-chain urokinase-type plasminogen activator) in rabbits with pulmonary embolized thrombi07/18/2019

Cooperative effects of the prostacyclin analogue taprostene and the thrombolytic agent saruplase (r-scu-PA) were studied in anesthetized rabbits with pulmonary thromboembolism. Thrombolysis was evaluated as decrease of the total weight and of the incorporated 125J-fibrin-radioactivity of the emb...detailed

Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected Saruplase (cas 99149-95-8) (r-scu-PA) in rabbit femoral artery thrombosis07/17/2019

Enhancement by anticoagulation of thrombolysis with infused or bolus-injected saruplase (r-scu-PA) has been studied using heparin and the thrombin inhibitor argatroban. In a rabbit femoral artery thrombosis model infusion of saruplase (3 – 12 mg/kg, 60 min) caused a dose-dependent thrombolysis....detailed

Thrombolysis with Saruplase (cas 99149-95-8) versus streptokinase in acute myocardial infarction: Five-year results of the PRIMI Trial07/16/2019

Background Short-term safety and efficacy of thrombolysis with saruplase in acute myocardial infarction have been shown in several trials. To assess long-term outcome of patients treated with saruplase or streptokinase for myocardial infarction, a 5-year follow-up of patients included in the Pro...detailed

Randomized, Double-Blind Study Comparing Saruplase (cas 99149-95-8) With Streptokinase Therapy in Acute Myocardial Infarction: The COMPASS Equivalence Trial fn107/15/2019

Objectives. This study sought to demonstrate the equivalence of saruplase and streptokinase in terms of 30-day mortality.Background. The use of thrombolytic agents in the treatment of acute myocardial infarction is well established and has been shown to substantially reduce post-myocardial infar...detailed

Comparison of Saruplase (cas 99149-95-8) and Alteplase in Acute Myocardial Infarction07/14/2019

Four hundred seventy-three patients with acute myocardial infarction (AMI) were treated with either saruplase (80 mg/hour, n = 236) or alteplase (100 mg every 3 hours, n = 237). Comedication included heparin and acetylsalicylic acid. Angiography was performed at 45 and 60 minutes after the start...detailed